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Abstract
Prediction of interaction between drugs or drug like compounds and targets, is of high
importance in drug discovery process as it provides important insights into therapeutic potential and possible adverse effects. As the experimental testing would be highly expensive,
laborious and time consuming, screening the molecules computationally before performing
experiments would be cost effective, faster and convenient as a method of approach. In
this study, I have developed computational models, leveraging machine learning techniques,
to predict drug-kinase binding affinities. The predictive model is mainly built using the
Random Forest (RF) machine learning method. This study is focused on kinases because
of their importance as drug targets for therapeutic use. The dataset encompasses the kinases and ligands binding information collected from Drug Target Commons (DTC) and
Pharos. The data was split into a training set (75%) and a test set (25%). The performance of the model was evaluated using several metrics and the best model achieved a
correlation coefficient (R) of 0.86, root mean square error (RMSE) of 0.52, concordance
index (CI) of 0.81, and Area Under a receiver operating characteristic Curve (AUC) of 0.95
during the internal 10-fold cross validation. An additional blind test was also performed
on synapse IDG-DREAM Challenge, which is a Drug-Kinase Binding Prediction Challenge
and RF model achieved AUC of 0.68. I demonstrated that RF model has the potential
to predict the binding affinity for the interaction of ligand and kinase based on structural,
physicochemical and atom pair based two-dimensional pharmacophore fingerprints. I also
compared the results based on grid search and random search methods. I observed that
there was no significant difference in model performance. However, random search reduced
the model building time significantly. I aim to build the better model based on other
machine learning approaches with more data in the future.
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Chapter 1
Introduction
Discovering a new drug is a long, expensive, and often haphazard process. The approaches
and the methodologies used in the drug discovery process have advanced over time. Out
of large number [1060 – 10100 ] of synthetically feasible molecules [40], we have to find a
compound satisfying the list of cirteria such as drug metabolism, bioactivity, synthetic
accessibility and pharmacokinetic profile and many more. According to the most recent
analysis by the Tufts Center for the Study of Drug Development (CSDD) [29], the average
cost to develop and approve a new drug is approximately 2.6 billion dollars. The Pharmaceutical Research and Manufacturers of America (PhRMA) claims that the overall process
for the drug to go into the market takes at least 10 years, of which around six to seven of
those years are spent undergoing clinical trials and usually less than 12 percent of drugs
that enter clinical trials get approved [3]. Thus, the modern Artificial Intelligence, especially machine learning (ML) approach plays a crucial role in the drug discovery process. It
is a new trending field which uses certain statistical algorithms with the help of computers
but without being explicitly programmed. If the success rate of drugs using ML approach
can just be raised by a very small amount, that would save billions of dollars.
Finding a compound that binds to a particular target is a one of the most challenging
parts of the drug discovery process. One of the recent studies by Ding et al. has reviewed
the importance of machine learning approach on predicting the drug target interactions on
a large scale using the information about the compounds and proteins. Proteins are the
good targets in drug design [5] and get activated or inhibited by drug compounds. The
interaction between drugs and targets facilitates the drug side effect prediction [34], drug
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repurposing [27] and many others. Biochemical experiment methods for drug target interactions are found highly costly and take a lot of time [45], where as computational methods
are efficient, faster and more convenient [15]. Docking and machine learning approaches are
two widely used methods to find the pharmacological profiles of drugs under development;
however, docking needs the high resolution X-ray crystal structures of proteins [15]. In
contrast, ML approach does not need the protein structures, thus it is considered as an
alternative choice. It relies on the chemical structures of potential ligands that are responsible for the binding. There are mainly three types of interactions studied in computer
aided drug discovery, namely compound (i.e., ligand) based, target based, and the most
recent system based frameworks. Quantitative structure-activity relationship (QSAR) is a
widely used ligand based technique that uses the statistics and analytical tools to analyse
the relationship between the structures of ligands and their corresponding effects [16]. Similarly, the target based method is solely based on the target information such as protein
sequence information for drug target prediction [20]. Another method is the system based
frameworks based on information of both compounds and targets. A recent study by Cichonska et al. [9] implemented the regression ML model for prediction and verification of
compound target bioactivity profiles. In the present study, I am focused on kinase target
family as they are used extensively to transmit signals and regulate complex processes in
cells. Dysfunction of protein kinases cause many diseases such as cancer and inflammatory
diseases. I have developed the prediction model for binding affinity prediction based on
the interaction profiles of kinases and their ligands. The prediction binding affinity values
of drug target complexes play a crucial role in the drug discovery process. It is usually
measured by dissociation constant (Kd ), inhibition constant (Ki ) and half maximal concentration (IC50 ). Binding affinity values are continuous values, however, most of the studies
about it are in binary classification problems. Some of the recent studies have done crucial
work developing the regression models to predict the binary affinity values. Pahikkala et
al [33] employed the algorithm named as KronRLS and later He et al. [14] proposed the
SimBoost to predict the binding affinity values but both use the similarity information
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obtained from 2D representations of compounds and used the traditional machine learning
method. Another recent work by Indra et al. [18] has implemented the regression models
using the Weka [13] tool to predict the protein ligand binding affinities and reported the
determination coefficient (R2 ) and RMSE as 0.76 and 1.31 respectively but rmse values
still high. In our study, I propose the Random forest regressor which is trained on an
extensively large data set obtained from the IDG-DREAM challenge [1] which is originally
from Drug Target Commons (DTC) [43]. I combined it with the data set obtained from
Pharos [31] . The final data set I have used contains the 97564 instances with 196 protein
kinases interacting with 6792 compounds. I have also evaluated our model on blind 17258
drug-kinase pairs that I filtered from the Metz data set [26].

1.1

Protein Kinases

Protein kinases are one of the largest families of genes in eukaryotes and covers around 2%
of the genome [23]. They have been intensively investigated as drug targets. Phosphorylase
kinase was the first protein kinase characterized biochemically which later led to discovery
of cAMP-dependent protein kinase which catalyzes the phosporylation and activation of
phosphorylase kinase [38]. Protein kinases modify the function of other proteins by attaching phosphate groups to them. They are key controllers of most biochemical pathways and
important in health and disease. By adding the phosphate groups to substrate proteins,
they direct the activity, localization and overall functions of proteins. They are particularly
prominent in signal transduction and coordination of complex functions such as cell cycle.
Out of 518 human protein kinases, 478 belong to a single superfamily whose catalytic domains are related in sequence, which can be clustered into groups, families and sub-families,
of increasing sequence similarity and biochemical domains [10].
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1.2

Classification of Kinases

Protein kinase is mainly comprised of AGC, CAMK, CK1, CMGC, MAPK, STE, TK, TKL
[12].
AGC: The AGC group of serine/threonine kinases is named after their homology to protein kinases A, G and C. It contains 60 members, including PKA, PKG and PKC. The
family comprises some intensely examined protein kinases (such as Akt, S6K, RSK, MSK,
PDK1 and GRK) as well as many less well-studied enzymes (such as SGK, NDR, LATS,
CRIK, SGK494, PRKX, PRKY and MAST)[35].
CAMK: CAMK stands for Calcium/Calmodulin-dependent kinase of enzymes. CAM kinases are divided into two groups: substrate restricted and substrate multifunctional, based
on substrate specificity. Their activation are modulated by increase in the concentration of
intracellular calcium ions (Ca2+) and activated CAMK is involved in the phosphorylation
of transcription factors. The concentration of free intracellular Ca2+ that range between
basally 50 nM to stimulated levels around 1-10 μM depending up on the cell type [44].
CK1: CK1 is an abbreviation of Casein Kinase 1. It is a small group of kinases that are
very distinct from other kinase groups but are very similar to each other in sequence. These
kinases are serine/threonine kinases with a preference for acidic substrates.
CMGC: The group name CMGC comes from the CDK family (Cyclin-Dependent Kinase),
the MAPK family (Mitogen-Activated Protein Kinase), the GSK family (Glycogen Synthase Kinase), the DYRK family (Dual specificity Tyrosine Regulated Kinase), and the
dual specificity CLK family (CDC2-Like Kinase).
MAPK: The name MAPK is an abbreviation of a mitogen-activated protein kinase that
get activated within the protein kinase cascades specific to the amino acids serine and threonine and involved in a variety of fundamental cellular processes such as differentiation,
proliferation, stress response, apoptosis, motility, and survival. Each cascade is initiated
by specific extracellular cues and leads to activation of a particular MAPK following the
successive activation of a MAPK kinase (MAPKKK) and a MAPK kinase (MAPKK)[28].

4

TK: TK stands for Tyrosine Kinases. These are major signaling enzymes in the process
of cell signal transduction, which catalyzes the transfer of ATP-gammaphosphate to the
tyrosine residues of the substrate protein. They are involved in several steps of neoplastic
development and progression. Their signaling pathways are often genetically or epigenetically altered in cancer cells to impart a selection of advantage to the cancer cells.
TKL: TKL stands for tyrosine kinase like and they are named so because of their close
sequence similarity to tyrosine kinases. These are diverse groups of families that resemble
both serine/threonine and tyrosine kinases, and function as dual specificity kinases.
STE: These are homologs of the yeast STE7, STE11, and STE20, which sequentially activate the MAPK family. The p21-activated kinases (Paks) are the prominent members of
these families, which are critical regulators of diverse signaling pathways. Their alterations
in Pak expression in human tumors makes them as an attractive new therapeutic agent [12].

1.3

Structure of Protein Kinases

The structure of protein kinase was first observed by X-ray crystallography in 1971 [17].
A typical protein kinase core consists of two lobes (or subdomains): the larger carboxy
terminal lobe (green) and the smaller amino terminal lobe (red). They are commonly
known as C-terminal and N-terminal. N terminal contains a series of β and one important
α helix, where as C terminal mainly consists of α helix. The lobes are connected by a short
polypeptide chain, which is known as the linker, or the hinge region as shown in figure(1.1).

1.4

Importantance of Protein Kinases

Protein kinases are important for a wide range of the cellular processes, mostly involved
in the signal transduction. They transfer a phosphate group from a molecule of adenosine
triphosphaste (ATP) onto a protein or other substrate which is known as phosphorylation.
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Figure 1.1: A typical protein kinase (Adopted from PDB 1IR3)
Phosphorylation plays an important role in various cellular processes such as cell division,
metabolism, survival and apoptosis. Deregulation of protein kinases cause many diseases
such as chronic myelogenous leukaemia, gastrointestinal stromal tumours and cancers as
well as non-malignant disorders. Therefore, kinases are attractive targets for both biological
research and drug development. The protein kinases undergo the following enzymatic
reaction.
+
MgATP1– + protein – O : H –→ protein – O : PO2–
3 + MgADP + H
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(1.1)

Figure 1.2: Enzymatic activity of a kinase (from, Tesi Di Dottorato, Padua@research)

1.5

Kinase Inhibitor

A protein kinase inhibitor is a type of enzyme inhibitor that blocks the action of one
or more protein kinases. They are important research tools to study cell functions and
human diseases. Targeted therapies with small molecule kinase inhibitors (KIs) are one
of the cornerstones in the treatment of many cancers. Most of the kinase inhibitors are
ATP-competitive and are called type I inhibitors because they compete with the nucleotide
phosphodonor substrate in the catalytic site of the enzyme. There are 48 small molecule
protein kinase inhibitors approved by United States Federal Drug Adminstration (US FDA)
and nearly all of which are orally effective except netarsudil [39].
Dar and Shokat have defined three classes of small molecule protein kinase inhibitor,
which are labeled as types I, II, and III [11]. Type I inhibitor is defined as a small molecule
that binds to the active conformation of a kinase in the ATP pocket. Similarly, the type
II inhibitor is defined as a small molecule that binds to an inactive conformation of a
kinase, and the type III inhibitor is defined as a non-ATP competitive inhibitor or allosteric
inhibitor.
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Table 1.1: Names of some diseases and involved kinases
Diseases
Cancer

Kinases

Diseases

Kinases

Essential hypertension

ERK, P38

Pulmonary hypertension

ALK1

Aurora, CK1d, CK2,
RTK, NRTK

Parkinson

JNK, DYRK1a

Inflamation

ERK, P38, JNK

Insulin dependent

GSK3, PKC

diabeties
Cardiovascular

Insulin independent

ERK

disease

GSK3, PKC

diabeties
GRSK3,

Down’s syndrome

DYRK1a

Alzheimer

PKC, ERK,
CDK5, CK1d

Craniosynostosis

FGFR

Infectious and parasitical

CK2, CK1

disease
Obesity

Schizophrenia

PKA

CAMKII

and depression

1.6

Enzyme Kinetics and Inhibition

Enzymes are protein catalysts which increase the rate of reaction without being consumed
in the process. The enzyme kinetics refers to the study of rate at which an enzyme works.
The study of enzyme kinetics help us to understand the catalytic mechanism of an enzyme,
its role in metabolism and also the drugs and poisons inhibition in its activity.
1.6.0.1

Substrates and Inhibitors

A substrate is a compound, for example, a drug, which is metabolized by an enzyme where
as an enzyme inhibitor is a molecule or compound that binds to an enzyme and binds
its activity and also may decrease the metabolism of substrates. Although enzymes are
8

absolutely essential for life, abnormally high enzyme activity can lead to disease conditions.
So, manipulation of enzyme catalysis with inhibitors is critical for prevention of infectious
diseases, cell growth, control of inflammatory response and more. The dissociation constant

Figure 1.3: Relation between Inhibitor concentration and IC50 (from, Chandra Mohan,
2014)
Kd measures the binding affinity of the substrate for enzymes. The smaller the value of Kd
the greater the biniding affinity is. Similarly, Ki is the inhibition constant of the enzymeinhibitor complex or the reciprocal of the binding affinity of the inhibitor to the enzyme and
the smaller the value of Ki , the smaller the amount of the medication needed in order to
inhibit activity of the enzyme. Another parameter IC50 is the concentration of an inhibitor
relative to substrate concentration producing the 50 percent inhibition to enzyme, that is,
binding is reduced by 50 percent. In enzymatic inhibiton assay, IC50 , the relation between
concentration at which the inhibitor causes a 50% enzymatic activity and inhibitor constant
(Ki ) can be expressed using the Cheng Prausoff model [8]
Ki =

IC50
[S]
1+
Km

(1.2)

where [S] is the experimental substrate concentration and Km is the concentration of the
substrate at which the enzyme activity is half minimal.
9

Chapter 2
Theoretical Background
2.1

Machine Learning

Machine Learning (ML) is a branch of artificial intelligence based on the idea that a system
learns from the data, looks for the patterns and makes decisions with minimal human
intervention. They are not being explicitly programmed by the people. Machine learning
is widely used now a days because of its ability to apply complex mathematical calculations
to big data automatically, quickly and iteratively. It has tremendously reduced the time
and expenses of the people in the modern world. It is so fascinating and effective in it’s
performance. There are many applications of it from virtual assistance to video surveillance,
customer support, social media services and much more. Some of the great examples of
machine learning are the self-driving Google car, recommendations on the side of web
pages, friend suggestions on Facebook, cyber fraud detection, etc. It is also becoming a
powerful and flexible tool in the field of medicine to analyze and predict the outcomes from
the biological and clinical data. There are two widely used machine learning methods:
Supervised learning and unsupervised learning.

2.1.1

Unsupervised Machine Learning Method

In this method, data has not any historical labels. So, the system is not told the output
and the algorithm must figure out what is going on in the data. The goal of this method is
to find the structure within the data. For example, for the data that contains the dogs and
cats images which are never seen, the machine has no idea about the features of dogs, but
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it can categorize into two clusters where the first may contain all the pictures of dogs and
the second may contain all the pictures of cats. Unsupervised learning method is further
categorized into algorithms, namely Clustering and Associating.

2.1.2

Supervised Machine Learning Method

In this method, algorithms are trained using the known input and output values. For
example, suppose when size, color and shape of a particular fruit is given. If the size is big,
color is red, and shape is rounded with a depression at the top, one can confirm that the
fruit is an apple. So, the structure of the data is already known, and the goal is to assign
the new data to the correct classes. For the input variables x and output variable Y, the
mapping function from the input to the output is as follows.
Y = f(x)

(2.1)

Supervised learning is further grouped into classification, regression, and forecasting.
Classification: If the data are being used to predict the categorical variables such as
’Yes’ or ’No’, ’1’ or ’0’, then supervised learning is also called classification. When the
output variables consist s of only two labels, this is called binary classification whereas the
output variable with more than two labels, is known as the multi-class classification. The
prediction of site of metabolism for FMO is an example of classification problem.
Regression: In this problem, the predicting values are continuous, for example, in between
0 to 1. A continuous output variable is a real-value. They are either an integer or floating
point value. I have used the regression method for prediction of the kinases’ inhibitors’
activity and drug metabolic properties.
Forecasting: In this method, predictions about the future are made based on the past
and the present data. It is mostly used to analyze the trends. For example, forecasting of
rainfall based on the current and previous year’s rainfall.
Following are the some of the examples of machine learning.
(I) Support Vector Machine:
11

Figure 2.1: Support vector machine (from, https://udemy.com)
Support vector machine (SVM) is the supervised machine learning that is based on the
concept of a decision plane that defines decision boundaries. A decision plane is the plane
that separates the set of objects have into different class memberships. SVM can be used
for both classification or regressions problems. For example, we have the data points in
two-dimensional space as shown below. For the new data in the future, we dont know
where they will fall either in the green area or in the red area. So, we have to separate
those data points with the help of a decision plane. This plane can be drawn in many ways
such as vertically or horizontally or diagonally as shown in Figure 2.1. However, we need
to find the optimal line among those all possible lines so that data will either fall in the
red zone or green zone. This overall process is known as the support vector machine. This
optimal line is the best decision boundary. SVM searches this line through the maximum
margin between two groups and the distance between the line and each one of these points
are in equi-distance. Therefore, the sum of these two distances has to be maximized in
order for the line to be the result of the SVM. Two points as shown in the figure are called
the support vectors.
(II) Random Forests
Random forest is a method running the decision tree method multiple times, giving us
the random forests. It can be used for both the classification and regression. A forest is
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Figure 2.2: Random forests
comprised of many trees. In general, it is said that the more trees it has, the more robust
a forest is. Random forests create decision trees on randomly selected data samples, get
predictions from each tree and selects the best solution by means of voting as shown in
figure 2.2. It is widely used for a variety of applications, such as recommendation engines,
image classification and feature selection. Since random forests are based on the decision
trees, let’s talk a little bit about the decision trees. Decision trees are predictive models
that use a set of binary rules to calculate a target value. There are of also two types,
classification and regression trees. Classification trees are used to create categorical and
regression trees are used for continuous data sets.
(III) Artificial Neural Network
As the name suggests, artificial neural networks (ANN) are the brain-inspired systems
which are intended to replicate the way that we humans learn. They are comprised of
artificial neurons, also known as nodes. ANN has anywhere from a dozen to millions of
artificial neural neurons arranged in a series of layers. ANN consist of input layers, output
layers, and hidden layers as shown in figure 2.3 most of the time. Input layer is the layer of
input signals also known as synapses that are passed to the neurons in the hidden layers.
Synapses are assigned with weights. Weights are crucial in ANN because that is how
ANN learns showing which signal is important, and which is not. Signals reached into the
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neurons are summed to form weighted sum. This weighted sum is applied to the activation
function. Based on the activation function neuron will either pass on the signal.

Figure 2.3: Artificial neural network
Activation Functions:
There are the many types of the activation functions. Following are the three important
activation functions that are widely used in artificial neural network.
(i) Rectifier Function
The mathematical form of rectifier (relu) function is:
φ(x) = max(x, 0)

(2.2)

It is one of the most used activation functions and the reason is it’s sparsity. Only the
positive values are allowed. Since the negative values are not passed, it will negate the
possibility of occurrence of a dead neuron and therefore speeds up the process. The drawback of the ReLU is that the function is zero for the negative values of x and therefore
gradient hits zero at those negative values. This will result in not adjusting the weights of
the neurons during back propagation.

(ii) Sigmoid Function
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Figure 2.4: Rectifier function

Figure 2.5: Sigmoid function

The mathematical form of sigmoid function is:
φ(x) =

1
1 + exp(–x)

(2.3)

It is a non-linear function. When the weighted sum is applied in the place of x, the output
of this function is in between 0 and 1. The large negative numbers are scaled towards 0 and
large positive numbers are scaled towards 1. It is continuously differentiable, monotonic,
and has a fixed output range. One of the drawbacks of this function is that it has the
problem of vanishing gradients. As you can see from the figure, when x, the input value to
the function, is really small, that is, towards –∞, the output of the sigmoid function will
be closer to zero. Conversely, when x is really big, that is towards ∞, the output of the
sigmoid function will be closer to 1. In those regions, the gradient is going to be very small
and even vanishes. This is problem is known as “vanishing gradients” problem.
(iii) Hyperbolic Tangent:
The mathematical form of hyperbolic tangent function is:
φ(x) =

1 – exp(–2x)
1 + exp(–2x)

(2.4)

The output of this function is from -1 to 1. Since its output is zero centered unlike to
sigmoid function, it’s more preferred than sigmoid function. The drawback of this function
is it also has the vanishing gradient problem.
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Figure 2.6: Hyperbolic tangent

2.2

Evaluation Metrics of ML Models

Models evaluation in machine learning is an essential part of the machine learning model
development process. There are several ways to measure the performance of the developed
model. We have summarized here the evaluation metrics of the classification as well as
regression models.

2.2.1

Classification ML Evaluation Metrics

(i) Confusion Matrix: As the name suggests, the output of the ML model is in the form
of the matrix. For example, let’s say we have a binary problem that has two outputs, 1 for
‘Yes’ and 0 for ‘No’. Then, the confusion matrix is as follows:

Figure 2.7: Confusion matrix

16

True Positive(TP): This is the case where we predicted ‘Yes’ and the actual is ‘Yes’.
True Negatives (TN): This is the case where we predicted ‘No’ and the actual is ‘No’.
False Positive(FP): This is the case where we predicted ‘Yes’ and the actual is ‘No’.
False Negatives(FN): This is the case where we predicted ‘No’ and the actual is ‘Yes’.
(ii) Accuracy: The Accuracy in terms of above parameters can be written as:
Accuracy =

TP+TN
TP+FP+TN+FN

(2.5)

(iii) Sensitivity: It is the number of true positives divided by the number of true positives
and the number of false negatives. It is also known as recall. The range of sensitivity is in
between 0 and 1. The best value is 1 and worst is 0.
Sensitivity =

TP
TP+FN

(2.6)

(iv) Specificity: It is calculated as the number of correct negative predictions divided
by the total number of negatives. It is also known as True negative rate. The range of
specificity is also 0 to 1. The best value is 1 and worst is 0.
Specificity =

TN
TN+FP

(2.7)

(v) Precision (Positive Predictive Value): Precision is also known as positive predictive value. It is calculated as the number of correct positive predictions divided by the
total number of positive predictions. The best precision is 1.0, whereas the worst is 0.0.
Precision =

TP
TP+FP

(2.8)

(vi) F1-Score: It is the harmonic mean of the recall and precision and can be written as:
F1 = 2 ×

Precision × Recall
Precision + Recall

(2.9)

F1 score is calculated as the weighted average of precision and recall. Therefore, both false
positives and false negatives are taken into account. F1 is usually more useful than accuracy,
especially if we have an uneven class distribution. Accuracy works best if false positives
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and false negatives have similar cost. If the cost of false positives and false negatives are
very different, its better to look at both precision and recall.
(vii) Mathew Correlation Coefficient (MCC): It is calculated as,
MCC =

(TP × TN) – (FP × FN)
(TP+FP)(TP+FN)(TN+FP)(TN+FN)

(2.10)

It is used to measure the quality of binary classifications. It takes into account true and
false positives and negatives and is generally regarded as a balanced measure which can
be used even if the classes are of very different sizes. The MCC is in essence a correlation
coefficient between the observed and predicted binary classifications; it returns a value
between -1 and +1. A coefficient of +1 represents a perfect prediction, 0 represents no better
than random prediction and -1 indicates disagreement between prediction and observation
(source: Wikipedia).

2.2.2

Regression ML Evaluation Metrics

(i) Mean Square Error(MSE): It measures average squared error of our predictions.
It calculates square difference between the predictions and the target for every input and
then averages those values. It can be obtained as (write equation):
N

1X
MSE =
(yi – ŷi )2
N

(2.11)

i=1

The lesser the value, the better the model is. It is non-negative, since were squaring the
individual prediction-wise errors before summing them. Its value is zero for the perfect
model.
(ii) Root Mean Square Error(RMSE): It is just the value obtained from the squared
root of root mean square error. The square root is introduced to make scale of the errors
to be the same as the scale of targets. So, it is written as:
v
u
N
u1 X
t
(yi – ŷi )2
RMSE =
N
i=1
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(2.12)

(iii) Pearson Correlation Coefficient: It is a widely used correlation statistic that
measures the degree of relationship between linearly related variables. For two variables x
and y, it can be calculated as:
P
P P
N( xy) – ( x)( y)
R= p P
P
P
P
[N x2 – ( x)2 ][N y2 – ( y)2 ]

(2.13)

(iv) Coefficient of Determination: Another way to evaluate the model is to measure
the coefficient of determination, which is written as R2 . Mathematical form of R-squared
is as follows:
R2 = 1 –

SSE
SST

(2.14)

where SSE is the sum of squared errors of our regression model and SST is the sum of
squared errors of our baseline model, they are calculated as
N

1X
SSE =
(yi – ŷi )2
N

(2.15)

i=1
N

1X
SST =
(yi – yi )2
N

(2.16)

i=1

where ŷ is the expected value and ȳ is the mean of the observed data. It is the square
of the correlation (R) between predicted scores and actual scores. Thus, its values ranges
from 0 to 1. R2 = 0 means that the dependable variable can not be predicted from the
independent variable. R2 = 1 means the dependent variable can be predicted perfectly
from the independent variable. R2 in between 0 and 1 is the measurement of how likely
the dependable variable is predictable.
(v) Concordance Index: CI measures the probability of two randomly drawn drug-target
pairs with different label values are in the correct order. That means the prediction for
the larger affinity is larger than the prediction of smaller affinity value. If f i , f j , yi and
yj are the predictions and actual affinity values in the case of larger and smaller values
respectively, CI can be obtained as:
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CI =

1 X
h(f i – f j )
Z y >y
i

(2.17)

j

where Z is the normalization constant, h(u) is the step function. h(u) is 1.0, 0.5 and 0.0
for u > 0, u = 0 and u < 0 respectively. The CI value lies in between 0.5 and 1.0. The
value 0.5 is for the random predictor where as 1.0 is for the perfect prediction.
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Chapter 3
Approach and Methodology
3.1

Data Preparation

This study is built on two drug target interaction data sets 1) Drug Target Commons
generated by Tang et al. [43] and 2) Target Central Resource Database generated by
UNM/NIH [30]. Both of these databases are publicly available drug target interaction
databases. The combined data set not only contained the the drug-target but also ligandprotein interaction information. It contained the compound id, standard inchiKey, compound names, synonyms, target id, target preference name, gene names, wildtype or mutant, mutation information, pubmed id, standard type, standard value, standard units,
assay format, compound concentration, substrate type, substrate value, assay description,
and many other information. I have removed the duplicate lines found in the data set.
The database had the Ki (inhibition constant), Kd (dissociation constant), and IC50 (half
maximal inhibitory constant) values representing the binding affinities of kinase inhibitors
complexes. I have focused only on Ki and Kd values. The data set had 5,77,061 lines
at the beginning. This combined data set had 2,207 targets. Since I am focused only on
kinases, I used the drug target interactions data set for 196 kinases. The final data set
contained 97,564 instances obtained from 196 protein kinases and 6,792 compounds and
also corresponding binding affinities. Kd or Ki values are transformed into log space, pKd
or pKi using the following equation. All the values are divided by 109 converting nano
Molar (nM) to Molar (M).
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Table 3.1: Summary of data Sets
Data Sets

Kinases

Compounds

Interactions

DTC and Pharos

196

6792

97496

Metz

148

240

17258


pKd = –log10

(a) binding affinity values in pkd

Kd
1e9


(3.1)

(b) binding affinity values in pki

Figure 3.1: Distribution of data sets

3.2
3.2.1

Molecular Features (Descriptors)
Protein Features

Features of all 196 protein kinases are obtained from a web server ‘PROFEAT’ [21] using
protein sequences. Protein sequences for all the kinases are extracted from NCBI [32].
The FASTA format or RAW format of sequence of protein is subjected as an input in a
window provided in the web server. Multiple sequences of proteins can be supplied as a
input in the form of text or csv file so that features of many protein sequences can be
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generated and saved conveniently. An input sequence of protein with less than eight amino
acids is not accepted by the server. Each generated file for each protein contains the 10
sets of commonly used structural and physicochemical features including 51 descriptors
and 1447 descriptive values. These total features can be divided into six groups which are
(i) amino acid, dipeptide composition (ii) Normalized Moreau-Broto autocorrelation (iii)
Moran autocorrelation (iv) Geary autocorrelation (v) Composition, transition, distribution
(vi) sequence order. Each group has been treated as an independent set of features.

3.2.2

Ligand Features

Molecular descriptors are obtained using the perl scripts ‘Topological Pharmacophore Atom
Pairs Fingerprints’ (TPAPF) and ‘Calculate Physicochemical Properties’ through MayaChemTools [42]. TPAPF is based on the topological cross correlation of generalized atom
type which is a simple molecular descriptor that leads to a compact, molecular size independent description of potential pharmacophores [2]. This representation scheme counts the
distance between atom pairs and then coded into the histograms representing the exhaustive fingerprint of the molecule. The distances are expressed as the number of bonds of the
shortest path connecting two nodes of non-hydrogen atoms in the molecular graph. Each
atom on node contains a specific type from one of hydrogen-bond donor(D), hydrogen-bond
acceptor (A), positively charged (P), negatively charged (N) or lipophilic (L). The number
of occurences of all possible pharmocophore point pairs (DD, DA, DP, DN, DL, AA, AP,
AN, AL, PP, PN, PL, NN, NL, LL) for each molecule is determined. Distances of up to ten
bonds for molecular representation, that is 15×10, leads to 150 dimensional vectors [41].
Large numbers of virtual compound libraries for similar structures can be searched based
on the correlation-vector representation. Each library molecule is compared with the query
vector. A measure of Euclidean distance can be used to measure the similarity between
each library molecule and query vector. The Euclidean distance between two molecules A
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and B is obtained by the following equation.
v
u 150
uX
B
D(A, B) = t (vA
i – vj )

(3.2)

i=1
B
where vA
i and vj represent the correlation vectors for A and B respectively. I have also used

to the physicochemical features of the compounds using the mayachem tools. The properties
of compounds that I have used as features are MolecularWeight, HeavyAtoms, MolecularVolume, RotatableBonds, HydrogenBondDonor, HydrogenBondAcceptors, SLogP, TPSA.
Molecular weight: Molecular weight is one of the most significant descriptors. It has
been correlated with a number of key parameters in drug discovery. The molecular weights
of the marketed drugs or drug candidates has been increasing [37]. It has also been found
that molecular weights in oral drugs approved in between 1983 and 2002 had 14 percent
greater molecular weight than those approved before 1983 [19]. Higher number of failures
in early clinical trials are found with the physical properties with low molecular weight.
Polar Surface Area: Molecules having a large polar surface area (PSA) may face difficulty in transiting biological membranes [4].
Rotatable Bonds: Molecular flexibility of a compound is an important property that is
frequently optimized in drug discovery process. The number of rotatable bonds are used
in regard to molecular flexibility.
Hydrogen Bond Donors or Acceptors: Lipinski [22] showed that most of marketed
drugs have fewer than 5 hydrogen bond donors and fewer than 10 hydrogen bond acceptors.
Hydrogen bonds are found to play key roles in drug discovery processes. The location of
the hydrogen bond is important to determine the potency and selectivity of a compound.
Similarly heavy atoms, Molecular volume, and SLogP are also key elements in drug discovery program.
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3.2.3

Machine Learning Model Development

Different modeling techniques have been developed to depict various aspects of the mathematical modeling of data. In the past decades, many statistical methods and stochastic
approaches have been proposed for prediction such as in one of the recent article [24], the
authors used stochastic models to describe a unique type of dependence of measurements
on time different types of data and obtained very low errors of estimated parameters.
In this study, I have used the machine learning approach aiming to predict the binding
affinity values of ligand-kinase interactions with low predictive errors. Since the binding
affinity values are quantitative values, I have used the Random Forest Regressor (RFR),
which is an ensemble of various decision Trees [7]. The model is optimized by grid search
method with 10 fold cross validation based on scikit-learn library machine learning library
for python [36]. Cross validation describes the process of splitting the whole data set into
x (say) parts and using each one of them sequentially as the test data set while combining
the others to the training data. I also developed model based random search method [6]
and compared the results with the grid search method. For RFR, I have tuned the hyperparmeters: n estimators, max features, and mini samples split as they are found effective
while developing the model for both grid search and random search methods.

Figure 3.2: Project work flow
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3.2.4

Grid Search Vs Random Search:

Hyperparameters are model specific properties which are fixed even before the model is
trained or tested on the data. Hyperparameter optimization is considered as the trickiest
part of the machine learning model as well as artificial intelligence in models development
processes. The main purpose of it is to find the best spot in the available space so that
the best set of hyperparameter leads to high precision and accuracy. There are several
parameter tuning techniques but grid search and random search are the most popular
methods.
Grid Search Method:
In this method, every combination of a preset of values of the hyperparameters are used to
train the model and among them, the best combination is chosen which ends up with best
results. It is usually considered as a good choice when we have a small set of parameters
to optimize. For each hyperparameter, we give a set of candidate values to explore from
range of all possible values. We train and evaluate the data for each combination and the
at the end we keep one which yields the best results. The main problem of the grid search
is that time increases exponentially as the number of parameters grow. For example, if
there are p parameters and each parameter can take r number of values, then running time
is calculated as O(rp ). But, when each parameter can take the different number of values,
then we simply multiply the all of them.
For example; a random forest regressor has a list of hyperparameters and among them,
some are found effective while developing the machine learning model such as n estimators,
max features, min samples split. These three are found helpful to boost the performance
of the model. So, the possible number of ways that the grid search run can be calculated
is as follows: if n estimators = [100,200,300,400,500], max features = [’auto’, ’sqrt’, ’log2’,
None], and min samples split = [2, 5, 10], Then total number of ways grid search run is
equal to (5*4*3)=60 and if we also use the cross validation as CV = 10, then 60*10 = 600.
That means the model runs for 600 times (i.e., 600 iterations).
Random Search Method:
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This idea was proposed by James Bergstra and Yoshua Bengio[6]. In this method, we normally provide the statistical distribution of each hyperparameters rather than any specific
set of parameters. The values are randomly picked on each iteration to train the model.
It is more generally a process of choosing a representative sample of parameter from the
entire space to know about the whole data. It is good in testing wide ranges of values and
normally ends to give the best results, however best parameters are not always guaranteed.
It is based on the notion that each hyperparameters are not equally important for the model
development. Random search is popular for large data sets. In high dimensional parameter
space, grid search performs worse with the same iterations because points become sparse.
As all the hyperparameters are not equally important, grid search wastes a lot of iteration
whereas random search is faster and saves a lot of time. For example; if we use the same
set of hyperparameters just like in grid search, then the number of iterations in random
search are actually determined by the value chosen for n iter and k-folds cross validation.
If we have chosen n iter = 10, and CV = 10, then the total number of iterations are only
10*10 = 100. So, if we compare with the grid search it is way faster than grid search.

Figure 3.3: Grid search vs random search (from, Random Search for Hyper-Parameter
Optimization[6], James Bergstra, Yoshua Bengio)

27

3.2.5

K-Fold Cross Validation

Cross validation (CV) is an important technique for tuning parameters and producing
robust measurements of model performance. There are several types of cross validation
techniques such as k-fold, leave one out cross validation (LOOV), nested, etc depending
upon the nature of data. For example, nested cross validation is used for time series data
where K-fold CV is not valid option while tuning the ML model. It is because the time
series data takes into account the temporal dependencies of the measurements [25]. Our
model is based on the K-fold cross validation. At first the data is divided into train and
test set. Test set is reserved for evaluation after the model selection. We have used k-folds
validation with CV=10. k-folds cross validation means the data is divided into k different
subsets where (k-1) are used to train the model and 1 remaining is used to test the model.
For each unique group, hold it as test set and the remaining sets as training set. So, the
model is trained with training set and evaluated by test set. If k = 10, then there are
10 unique processes as every time 1 unique test is used to evaluate the model and other
remaining sets are used to train the model. The overall evaluation of the model is the
average value of all values.

Figure 3.4: K-fold cross validation (from, Karl Rosaen, http://karlrosaen.com)
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3.3

Evaluation of Machine Learning Models

This is an important part of the machine learning where we evaluate the developed models
on the basis of some statistical parameters. Since this is a regression problem, we have
evaluated the model using Root Mean Square Error (RMSE), Pearson’s correlation coefficient (R), Concordance Index (CI), and Area Under the ROC Curve (AUC). We used the
tools that are made avilable by IDG-DREAM challenge [1] to evualute the model. Some
of them are as summarized below.

3.3.1

Evaluation Metrics

Concordance Index: Since the binding affinities in drug target interactions are continuous values, one of the evaluation metrics we used was the Concordance Index (CI) for the
prediction accuracy [33]. CI measures the probability of two randomly drawn drug-target
pairs with different label values are in the correct order. That means the prediction for the
larger affinity is larger than the prediction of smaller affinity value. If di , dj , xi and xj are
the predicted and actual affinity values in the case of larger and smaller binding affinities
respectively, CI can be obtained as:

CI =

1 X
h(di – dj )
Z x >x
i

(3.3)

j

where Z is the normalization constant, h(u) is the step function. h(u) is 1.0, 0.5 and 0.0
for u > 0, u = 0 and u < 0 respectively. The CI values lies in between 0.5 and 1.0. The
value 0.5 for the random predictor where as 1.0 for the perfect prediction.
Root Mean Squre Error(RMSE): If Ba and Bp are the actual and predicted binding
affinities. Error can be calculated as:
Error(Ei ) = Ba(i) – Bp(i)
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(3.4)

Mean Square Error (MSE) is calculated as mean of differences of actual binding affinity
values and calculated binding affinity values.
N

1X 2
MSE =
Ei
N

(3.5)

i=1

√
RMSE =

MSE

(3.6)

RMSE value depends up on the nature of data sets. We always try to minimize it. It should
be similar for both training and test set. If values are higher in test than the training set,
it is likely that we have badly over fit the data.
Correlation Coefficient Coefficient (R):
N

1X
Ba(i)
N

Ba =

(3.7)

i=1
N

1X
Bp =
Bp(i)
N

(3.8)

i=1

PN
R = qP
N

i=1 (Ba(i)

i=1 (Ba(i)

– Ba )(Bp(i) – Bp )
P
2
– Ba )2 N
i=1 (Bp(i) – Bp )

(3.9)

R measures the linear relationship between the actual and predicted binding affinity scores.
It lies in between -1 and 1.
Area Under the Curve (AUC): The area under the Receiver Operating Characteristic
(ROC) curve is generally adopted in binary classification problems. However, it can also be
used to measure the regression problems by converting the quantitative values into binary
values by selecting thresholds. There are different ways to measure AUC for regression
problems. We have measured the average AUC converting the actual compound kinase
interaction values (i.e, binary affinities) into binary labels given certain interaction thresholds. In roc curve the True Positive Rate (TPR) (i.e., sensitivity) is plotted in function of
the False Positive Rate (FPR) (i.e., 1 – specificity) for different cut-off points.
TPR =

TP
(TP + FN)
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(3.10)

FPR =

FP
(FP + TN)

(3.11)

Accuracy is measured by the area under the ROC curve. An area of 1 (i.e, 100%) repre-

Figure 3.5: Area under ROC curve
sents a perfect test; an area of .5 (i.e, 50%) represents a worthless test (or random test).
Therefore, the closer the ROC curve is to the upper left corner, the higher the overall
accuracy of the test.
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Chapter 4
Results and Discussions
4.1

Results

The performance of RFR model by grid search method and random search method is shown
in table 4.1 and 4.2. The performance of model with increasing number of trees for both
test and external sets are shown tables 4.3 and 4.4.
Table 4.1: Performance of model developed by grid search method
Grid search method
Test data set

Metz data set

R

RMSE

CI

avg. AUC

R

RMSE

CI

avg. AUC

0.864

0.523

0.814

0.959

0.725

0.532

0.74

0.938

Table 4.2: Performance of model developed by random search method
Random search method
Test data set

Metz data set

R

RMSE

CI

avg. AUC

R

RMSE

CI

avg. AUC

0.862

0.525

0.813

0.959

0.723

0.533

0.738

0.935
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Table 4.3: Performance of model on test set with increasing the the number of trees

n-estimators

Pearson cor. coeff

RMSE

Concordance Index(CI)

avg. AUC

(R)
50

0.859

0.531

0.809

0.957

100

0.861

0.527

0.812

0.959

200

0.862

0.525

0.813

0.959

300

0.863

0.524

0.813

0.959

400

0.863

0.524

0.813

0.959

500

0.863

0.523

0.814

0.959

800

0.864

0.523

0.814

0.959

1000

0.864

0.523

0.814

0.959

(a) R vs number of trees

(b) RMSE vs number of

(c) time vs number of trees

trees

Figure 4.1: Plots showing the performance of RFR model on test data set
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Table 4.4: Performance of RFR model on external data set with increasing the the number
of trees

n-estimators

Pearson cor. coeff

RMSE

Concordance Index(CI)

avg. AUC

(R)
50

0.719

0.537

0.736

0.932

100

0.72

0.536

0.737

0.934

200

0.723

0.533

0.739

0.935

300

0.723

0.533

0.739

0.936

400

0.724

0.533

0.74

0.936

500

0.724

0.533

0.74

0.937

800

0.725

0.532

.74

0.938

1000

0.725

0.532

0.74

0.938

(a) R vs number of trees

(b) RMSR vs number of trees

Figure 4.2: Plots showing the performance of RFR model on external data set
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(a) Area under the ROC curve for test data set

(b) Area under the ROC curve for Metz data set

(avg. AUC=0.959)

(avg. AUC=0.938)

Figure 4.3: Plots showing the area under the ROC curve.

(a) Actual vs predicted binding affinity of test

(b) Actual vs predicted binding affinity of

data set

Metz data set

Figure 4.4: Scatter plots for actual vs predicted binding affinity of test and external data
sets.
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Table 4.5: Results of IDG DREAM Drug-Kinase Binding Prediction Challenge for our
model and best model in challenge
Round 1b

Round 2

Model

Our

Pearson

Spearman

(R)

(ρ)

0.368

0.316

0.60

0.689

0.283

1.223

0.544

0.556

0.711

0.78

0.40

1.025

CI

AUC

F1

rmse

Spearman

AUC

rmse

0.291

0.688

1.14

0.527

0.794

0.897

(ρ)

model
Best
model
based
on
AUC
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4.2

Discussion of Results

The agreement between the binding affinity values were evaluated in three different ways.
First off, the model was evaluated by blind test set (25%) and showed the highest consistency with a Pearson correlation coefficient of 0.86. Other evaluated scores were rmse
0.52, concordance index score 0.81, and average AUC 0.95. Since the model was evaluated
by internal 10 folds cross validation where each different test out of 10 sets are internally
evaluated, it is a purely unbiased model. I tested the model on another blind data set by
Metz et al. I compared and excluded the compound target pairs which are common with
our data set. There were 17,258 completely new compound kinase pairs containing the
binding affinity (pKi ) values. The scores obtained for Metz data set were slightly lower
than the test data set with R 0.72, RMSE 0.53, CI 0.74 and avg. AUC 0.938; however,
the RMSE and avg. AUC scores were still promising. The low value of RMSE shows that
predicted values were close to actual values and the high value of avg-auc indicates the
power of the model to discriminate between the true positives and negatives. I observed an
increase in the correlation coefficient with the increase in number of trees; however, it was
not improving much after 800, so I stopped at 800. Increase in number of trees raised the
performance of model to a certain level but after that it only increased the computational
cost.
The model was developed based on both grid search method as well as random search
method with in same parameter space. I did this because I wanted to compare the computational cost and model performance developed under these two widely popular methods.
The hyperparameters in RFR which were effective to improve the model performance were
namely, n estimators (or number of trees), max features and min samples split. The performance of model was almost same for both grid search and random search methods [6]. However, the computational cost was significantly reduced by random search method. Thus,
random search method gave the similar results in a short interval of time compared to grid
search method.
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The model was also tested in IDG-DREAM challenge and scores obtained in round 1b
and round 2 are as shown in table 4.5. Test set of round 1b contains the 430 pKd values
between 207 kinases and 25 compounds and round 2 test set contains the 394 pKd values
between 199 kinases and 70 compounds. I was at 13th (based on AUC) and top 29th (based
on Pearson correlation coefficient) at round 1b out of 216 submitted scores and at top 41th
(based on Spearman correlation coefficient) and 32th (based on AUC) position out of 101
submitted scores. The scores obtaied were lower than expected. However, I worked more
even after the challenge to increase the performance of the model. Basically, more relevant
features were added that actually boosted up the model performance to some extent.
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Chapter 5
Conclusion
I proposed Random Forest Regressor (RFR) machine learning model to predict the ligand
kinase binding affinity using the drug or drug like compounds and targets information. The
performance of model showed that RFR model based on structural, physicochemical and
atom pair based two-dimensional pharmacophore fingerprints has the potential to predict
the binding affinity values. The model was developed using both grid search and random
search methods under the same parameter space. I observed that hyperparameters namely,
n estimators, max features and min samples split in RFR were found effective to tune the
best model. The running time and performance of the model based on grid search and
random search methods were compared. The results based on two methods were not significantly different. However, random search reduces the model building time significantly.
I also observed that increase in number of trees hardly improved accuracy of model but increased the computational time instead. As database contained both dissociation constant
(Kd ) and inhibition constant (Ki ), the performance of model showed that these values can
be combined to develop the machine learning model. As a future work, I will focus on
building better model based on other machine learning methods with more data.
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